Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT01276223 Completed - Dry Eye Disease Clinical Trials

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.

NCT ID: NCT01272414 Withdrawn - Clinical trials for Graves Ophthalmopathy

Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction

Start date: January 2011
Phase: Phase 4
Study type: Interventional

Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent stage lid position. This investigation aims to examine the properties of this relationship.

NCT ID: NCT01256580 Withdrawn - Myopia Clinical Trials

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

CNV
Start date: August 2010
Phase: N/A
Study type: Interventional

Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes. The limitation of this type of treatment is the necessity for frequent intraocular injections. The purpose of this study is to determine if using anti-VEGF therapy in combination with photodynamic therapy can reduce the number of treatments needed with monotherapy while achieving similar visual results. There are ongoing multicenter trials evaluating combination therapy in patients with wet AMD but no similar trial for patients with CNV due to non-AMD causes. Therefore, in this study the investigators will focus on patients with CNV not due to AMD.

NCT ID: NCT01240343 Completed - Eye Diseases Clinical Trials

Creation of the Biobank Related to Eye Disease

BioBank
Start date: June 2009
Phase: N/A
Study type: Observational

The purpose of this study is to develop a BioBank (a specialized lab) and collect blood, fluids and/or other tissue samples to study eye diseases.

NCT ID: NCT01239069 Completed - Dry Eye Clinical Trials

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Start date: November 2010
Phase: Phase 2
Study type: Interventional

Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease

NCT ID: NCT01235234 Completed - Clinical trials for Keratoconjunctivitis Sicca

Trial of CF101 to Treat Patients With Dry Eye Disease

Start date: July 2011
Phase: Phase 3
Study type: Interventional

Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.

NCT ID: NCT01225146 Terminated - Eye Diseases Clinical Trials

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

RAVE2
Start date: October 2010
Phase: Phase 1
Study type: Interventional

The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.

NCT ID: NCT01217762 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical feasibility of the IRay System for the treatment of wet age-related macular degeneration (AMD).

NCT ID: NCT01135511 Completed - Dry Eye Syndromes Clinical Trials

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

NCT ID: NCT01114503 Terminated - Clinical trials for Graves Ophthalmopathy

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

Start date: July 7, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease). There is currently no alternative therapy available for this condition other than treatment with steroids, or radiotherapy and surgery. The study also includes a comparison of the current steroid treatment, methylprednisolone, with the proposed new otelixizumab treatment.